Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (9513)	1/30/2003 10:21:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

<<80-90 % I would say. >> I don't agree. Iressa was the subject of multiple well contolled trials. I am not sure Velcade will get to the committee as the FDA may not accept the application. They do not like to even consider approving drugs without a well controlled trial. From what I have seen Thalomid has as good response rates in refractory patients as Velcade. I am not saying the drug does not work or will not eventually get approved. The companies actions seem desperate to me.We will see. V1